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Methylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity
Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic
treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes.
We aimed to map current evidence regarding neurological and psychiatric outcomes, adverse or beneficial, of
long-term MPH (>1 year) treatment in ADHD. We coded studies using a “traffic light” system: Green: safe/
favours MPH; Amber: warrants caution; Red: not safe/not well-tolerated. Un-categorisable study findings were
coded as “Unclear”.
Although some evidence suggests an elevated risk of psychosis and tics, case reports describe remission on
discontinuation. Several studies suggest that long-term MPH may reduce depression and suicide in ADHD.
Evidence suggests caution in specific groups including pre-school children, those with tics, and adolescents at
risk for substance misuse.
We identified a need for more studies that make use of large longitudinal databases, focus on specific neu-
ropsychiatric outcomes, and compare outcomes from long-term MPH treatment with outcomes following shorter
or no pharmacological intervention.
1. Introduction
Methylphenidate (MPH) is the most commonly prescribed medica-
tion for children with Attention Deficit/Hyperactivity Disorder (ADHD)
in many countries. As ADHD is a developmental disorder that may
persist across the lifespan, MPH is often prescribed over long periods of
time: Wang et al. (2016b) found that in Taiwan, over a third of patients
with ADHD treated with immediate release MPH (IR-MPH) and nearly a
half of those treated with osmotic release oral delivery system MPH
(OROS-MPH) were still taking MPH two years after treatment initiation.
A follow-up investigation of participants in the United States Multi-
modal Treatment of Attention Deficit Hyperactivity Disorder (MTA)
study (Molina et al., 2009) showed that at 8 years after treatment in-
itiation, 32.5% were still taking medication, including MPH, for over
50% of days. Concerns about a broad range of possible adverse effects
of long-term stimulant treatments have been highlighted in the media
and by some interest groups, scientists and health professionals (Klein-
Schwartz, 2002).
In 2009, after reviewing the available research evidence, the
Committee for Medicinal Products for Human Use (CHMP) concluded
that the ratio of benefit-to-risk for MPH when used for the authorized
indications, such as ADHD, was favourable (European Medicines
Agency, 2007). However, they also noted that more data were needed
on long‐term effects in children and young adults, including neurolo-
gical and psychiatric effects. In particular, CHMP noted a range of
psychiatric adverse events, including aggression, psychosis, mania, ir-
ritability and suicidality, and suggested that methylphenidate may play
a causative role in the development of serious psychiatric disorders.
The objective of the European Union-funded ADDUCE (Attention
deficit/hyperactivity disorder drugs use chronic effects) project, was to
address this knowledge gap (see www.adhd-adduce.org for more in-
formation, grant agreement number 260,576). In the current study, we
aimed to map the current evidence base regarding adverse neu-
ropsychiatric effects, including behavioural effects, of long-term MPH
treatment (treatment duration of a year or more), including long-term
effects of such treatment.
Investigating potential adverse neuropsychiatric effects of any
treatment for ADHD is complicated by comorbidity and the symptom
overlap between ADHD and other neuropsychiatric conditions. These
include mood, anxiety and substance use disorders (SUDs) (Kessler
et al., 2006); bipolar disorder (Marangoni et al., 2015); psychotic-like
symptoms (Hennig et al., 2017); and sleep disorders (Silvestri et al.,
2009). In turn, in children with Tourette Syndrome (TS) (Freeman
et al., 2000) and epilepsy (Salpekar and Mishra, 2014) there is a high
prevalence of comorbid ADHD. Treatment with MPH to address the
symptoms of ADHD may help with some of these comorbid symptoms.
However, being a psychotropic drug, it also has the theoretical poten-
tial to induce or exacerbate them. Similarly, while effective treatment
with MPH during childhood and adolescence may reduce the risk of
adverse neuropsychiatric outcomes, prolonged exposure to any psy-
choactive drug during development has the theoretical potential to
raise the risk of at least some neuropsychiatric disorders.
The question as to whether long-term MPH treatment has adverse
neuropsychiatric effects, either during or after prolonged treatment, is
therefore not only clinically important, but particularly challenging to
answer. For example, ADHD severity may be an important potential
confounder as it may be associated with both the need for long-term
MPH therapy and high levels of underlying neuropsychiatric co-
morbidity. The problem of disentangling the elevated risks of adverse
outcomes arising from ADHD itself or from the risks posed by exposure
to the drugs used to treat it can be approached in a variety of ways and
at many units of analysis, from individual longitudinal case studies to
nationwide cohort studies. Each approach is likely to contribute re-
levant information. The purpose of this study was to provide as com-
plete a picture as possible of the evidence base to date.
Our investigation was submitted to Prospero (registration number
CRD42013005049). Our initial aim, as documented in the Prospero
submission, had been to delineate the adverse neuropsychiatric effects
of long-term methylphenidate use, using "group-based analyses sepa-
rately for each adverse symptom; quantitative versus narrative synth-
esis depending on number of studies to be entered in the final analyses."
However, our searches revealed a highly heterogeneous evidence base,
with a wide range of methodologies, outcomes of interest, treated po-
pulations, and comparators, which precluded meaningful quantitative
synthesis for many outcomes. It therefore became evident that the
priority was to provide an “evidence map” (Hetrick et al., 2010; Miake-
Lye et al., 2016) that would help prioritize the research agenda. In this
approach, study parameters are systematically extracted from studies
that meet eligibility criteria, and tabulated under headings decided a
priori. This table can then be interrogated to address specific questions
of interest.
We set out to produce an evidence map of the research literature
relating to the potential adverse neuropsychiatric effects of long-term
MPH treatment, defined as treatment for one year or more. Our search
embraced investigations designed to investigate both adverse and po-
tentially beneficial long-term outcomes of long-term treatment.
2. Method
2.1. Data sources and selection
We searched the Medline, Embase, and Psychinfo publication da-
tabases for terms relating to ‘’ADHD’’, ‘’methylphenidate’’, ‘’tics’’, ‘’self-
injury’’, ‘’mood disorders’’, ‘’psychoses’’ ‘’substance use’’, ‘’epilepsy’’,
‘’sleep disorders’’, ‘’dyskinesia’’ (see Appendix for search strategy de-
tails).
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2.1.1. Inclusion criteria
A study was included if:
• It was an original full article that provided evidence regarding po-
tential neurological, psychiatric or behavioural adverse effects of
MPH in humans of any age. We included studies that investigated
any potential neurological, psychiatric or behavioural outcome of
MPH treatment (outside the core symptoms of ADHD), irrespective
of whether they were hypothesised to be positive or negative.
• The participants had been diagnosed with the disorder variously
referred to as: ADHD; Attention Deficit Disorder (ADD) with or
without hyperactivity; hyperkinetic reaction of childhood; hyper-
active disorder, or hyperkinetic disorder.
• It was clear that the mean, median or modal treatment duration was
12 months or more.
2.1.2. Exclusion criteria
A study was excluded if:
• It was clear that the indication for treatment with MPH was not
ADHD.
• The mean or most common duration of treatment was no more than
12 months’ duration, and evidence of harm consisted only of adverse
events (AEs) recorded during that 12 month exposure. Studies
where the most common duration of treatment was 12 months were
included if potential adverse outcomes were evaluated at or later
than 12 months.
• It was not possible to separate the effects of MPH from other forms
of treatment.
2.1.3. Screening
The search was conducted in two waves. The first search included
records up to January Week 3, 2013, and returned 4681 unique records.
One researcher screened titles and abstracts for relevance, and a
random 20% of the exclusions were checked by a second researcher.
Full-text copies were obtained for the remaining records (N=435).
These were then screened using our full inclusion and exclusion criteria.
Records in languages other than English were assessed by a person with
proficient ability in that language. All full-text exclusions were checked
by a second investigator.
In the second wave of searches, the same search was iteratively
updated using the same search terms, the final search being on 19th
February 2019. This process returned a further 2215 unique records. In
this wave, only English-language articles were included for full-text
review (N=280). All exclusions at both title and abstract screening
stage and at full-text screening stage were checked by a second in-
vestigator.
2.2. Data extraction and mapping
Our data extraction tool was developed in Microsoft Excel, with
drop-down menus for categorical items, and free-text cells as appro-
priate. It was piloted on six included studies, after which further re-
finements were made where necessary. Investigators extracted data
from the full texts, highlighting areas of uncertainty for resolution
through discussion. Data headings fell into five broad categories:
1 Study characteristics, e.g. aims, design, setting
2 Sample characteristics, e.g. age range, comorbidities, gender,
sample size, diagnostic criteria
3 Treatment details, e.g. treatment duration, MPH formulation, con-
comitant treatments, comparator treatment where relevant
4 Potential adverse outcomes addressed1
5 Study conclusions, categorised using a “Traffic-light” system (“Yes”,
“Proceed with Caution”; “No”; “Unclear”)
• For comparative studies: Does the study overall favour MPH?
• For non-comparative studies: Do the authors conclude that MPH is
safe/well-tolerated?2
For the comparative studies, if the comparator was another active
treatment, we coded the result as “Yes” if the outcome favoured MPH,
or “No” if it favoured an alternative. If there was no clear difference
between comparators, we coded the result as “Yes” if the outcome was
beneficial for all comparators, and “Proceed with Caution” if the risk
associated with all treatments was low. In all other cases, we coded the
result as “Unclear”. Where the comparator was “no treatment”, we
coded the result as “Yes” only if the outcome was positively better for
MPH. For studies that showed significant adverse effects of MPH, we
coded the result as “Proceed with Caution” unless the result clearly
contraindicated the use of MPH, in which case it would be coded “No”.
Any other result was coded as “Unclear”.
The full list of headings is given in Table 1: Data map headings. The
evidence map file itself is available in Supplementary materials.
Following data extraction, we used pivot tables to generate tabu-
lated summaries of the evidence for each outcome. Narrative summa-
ries made use of study-specific information as appropriate.
3. Results
Sixty-four publications met our criteria for inclusion, with pub-
lication years ranging from 1971 to 2018. Numbers of publications
included and excluded at each stage of the process are given in the
PRISMA diagram in Fig. 1.
Publications consisted of 39 group studies, eight case series studies,
and 17 single case studies. We treated each case within a case series as a
separate item of evidence, and applied our inclusion and exclusion
criteria to each case. In three of the case-series publications (Kazanci
et al., 2015; Schubiner et al., 1995; Sprafkin and Gadow, 1993) two of
the individual cases reported met inclusion criteria. The final evidence
map therefore consisted of 67 items of evidence: 39 group studies, and
28 individual case reports extracted from 25 publications. Of the 39
group studies, we coded 28 as comparative designs (including both
categorical and continuous comparators) and 11 as non-comparative.
3.1. Study characteristics
3.1.1. Study designs
Of the 28 comparative studies, 23 were observational cohort stu-
dies, and five were controlled trials. Three of the controlled trials were
Randomized Controlled Trials (RCTs), and two were time-series treat-
ment-withdrawal challenge studies (see Table 2 for further details). Of
the 11 non-comparative group studies, six were prospective open-label
longitudinal studies, and five were retrospective studies (Table 3). Of
the 25 publications contributing to the 28 case reports, eight were case
series with a common theme and 17 were single case reports (Table 4).
Investigating potential harms of MPH treatment was the primary
aim in all the non-comparative studies, and all but one of the case
studies. However, in 9 (23%) of the comparative studies, investigation
of harms was a secondary aim. In most of these (7/9), the primary aim
was investigation of long-term neuropsychiatric outcomes in children,
adolescents or adults with ADHD, with MPH treatment as a potential
modifier of outcome (see Fig. S1.1 for a summary of study designs and
aims, broken out by study type).
1 Including outcomes anticipated in the study to be beneficial.
2 This determination was based on our reading of the authors’s conclusion.
Note that authors’ criteria for safety/tolerability may differ between studies.
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Table 1
Data map headings. Data map headings. NR=Not Reported.
Heading Explanation Entry
First author, year Study identifier in first author-date form Free text
Investigation of harms of long-term MPH use Was investigation of harms an explicit aim of
the study?
Primary aim, Secondary aim, Unclear aim, Post-hoc reporting
Study design What was the study design? Systematic review, RCT, Cluster RCT, Cross-over RCT, Non-randomized
Controlled Trial, Comparative Cohort, Nested Case-control, Case-control,
Non-comparative Trial, Non-comparative Cohort, Time Series, Case-series,
Case Report, Survey, Other
Study design -Other (text) Study design details if not otherwise specified Free text
Study related to Postmarketing Surveillance
Program
Whether or not the study was a post-marketing
surveillance study.
Yes/No
Centre How many centres in the study? Single, Multi, NR
Study Funding How was the study funded? Industry, Non-Industry, Unclear, NR
Study Location In which geographical region did the study take
place?
North America, Central or South America, Africa, Europe, Middle East, South
Asia, Asia Pacific, Australia or New Zealand, Multi-region NR
Multi-region Study location details if not otherwise specified Free text
Sample size Total sample study size, including data not
analysed
Integer
Does this study report neuropsychiatric harms? Does this study report neuropsychiatric harms? Yes, No (stop further data extraction)
Study setting What was the setting for the study? Community or school, Hospital or clinic, Prison/forensic, NR
Data analysis level Was the relevant data analysis conducted at
study level or at subgroup level?
Study level, Subgroup level
N analyzed What was the sample size of the group or
subgroup analysed
Integer
Duration of most common follow-up time
point in years
When was the followup data collected? Integer
Study population description What was the study population? Free text
Notable eligibility criteria impacting
generalisability
What were the eligibility criteria? Free text
Age category How old were the participants? < =5, > 5-< 18, < 5-< 19, Adults only, Adolescents only, Mixed, Other
category, Unclear or NR
Age category-other Age of participants if not otherwise specified Free text
Sex/gender What was the gender composition of the
sample?
Females only, Males only, Mixed (predominantly females), Mixed
(predominantly males), Mixed, NR
ADHD diagnostic criteria What criteria were used for ADHD diagnosis? ICD, DSM, ICD or DSM, Other, NR
ADHD subtypes What was the ADHD subtype composition of the
sample?
Combined, Inattentive, Hyperactive/impulsive, Mixed, Other, NR
Notable ADHD comorbidity 1 (analysis level) What, if any, notable comorbidities were
reported? If more than one, give the most
notable.
Anxiety, Autism spectrum/communication, Bipolar disorder, Depression,
Dyskinesias, Eating disorder, Intellectual disability (IQ < 70), Obsessive
compulsive, ODD/CD, Psychosis/hallucinations, Seizures/EEG abnormalities,
Self-injury/suicidal thoughts/behaviours, Sleep disorders, Specific learning
impairment/learning disability, Substance use disorder, Tics/Tourette
syndrome, Other, NR, None
Notable ADHD comorbidity 1 -other If “other” entered for previous heading, specify
the most notable comorbidity here.
Free text
Notable ADHD comorbidity 2 (analysis level) What additional comorbidities, if any, were
reported? If more than one, enter “Mixed”.
Anxiety, Autism spectrum/communication, Bipolar disorder, Depression,
Dyskinesias, Eating disorder, Intellectual disability (IQ < 70), Obsessive
compulsive, ODD/CD, Psychosis/hallucinations, Seizures/EEG abnormalities,
Self-injury/suicidal thoughts/behaviours, Sleep disorders, Specific learning
impairment/learning disability, Substance use disorder, Tics/Tourette
syndrome, Other, Mixed, NR, None
Notable ADHD comorbidity 2 -other If “Other”, or “Mixed” entered for previous
heading, enter all other comorbidities reported.
Free text
Intervention Was the MPH intervention investigated
combined with another intervention?
MPH, MPH+Other
Intervention-Other If “other” entered for previous heading, specify
here.
Free text
MPH Release type What was the MPH release-type? Immediate release, Modified release, Transdermal, Mixed, Unclear or NR
MPH formulation What was the MPH formulation? Concerta XL, Equasym XL, Medikinet XL, Ritalin SR, Ritalin LA, Mixed,
Unclear or NR
MPH dose format How was the MPH dose quantified? Mean, Median, Range, One dose, Other, NR
MPH dose format – other MPH dose format if not otherwise specified Free text
MPH dose (numbers only) What was the MPH dose? Number
Dose Unit What were the MPH dose units? Free text
Most common treatment duration in months What was the most common treatment duration
in months?
Integer
Comparator category For comparative studies: what was the
comparator?
No treatment or placebo, Other stimulant, Other non-stimulant drug, BT,
Other treatment, Mixed, Multiple comparators, NA (single group)
Specific Comparator(s) – when multiple
comparators or "other treatment"
For comparative studies: what was the
comparator if not otherwise specified?
Free text
Notable concomitant treatment Specify any notable concomitant treatment. Bupropion, Clonidine, Guanfacine, Melatonin, Mood stabiliser, Other, Mixed,
NR
Notable concomitant treatment-Other Any notable concomitant treatments if not
otherwise specified
Free text
(continued on next page)
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3.1.2. Sample sizes
Sample sizes in the comparative studies ranged from N=5 to
289,840, the two smallest being within-subject time-series designs. The
eight largest studies all made use of national/state-wide databases. For
the non-comparative group studies, sample sizes ranged from N=18 to
228. For sample size histograms see Fig. 2.
3.1.3. Participants
3.1.3.1. Age and gender. The majority of studies were of children and/
or adolescents, sometimes extending into young adulthood by the time
of the reported outcomes. The age and gender composition of the group
studies is shown in Fig. S1.2. Twenty-two of the case reports were of
children or adolescents (20 male), and six were of adults (four male).
3.1.3.2. Diagnoses
3.1.3.2.1. Diagnostic terms and criteria for ADHD. Diagnostic terms
reflected the changing definitions and terminology for ADHD over the
extensive range of publication dates (1971–2018) of the included
studies. In studies in which the original diagnosis had been made
prior to 1980, the diagnostic term reflected the DSM-II label
“hyperkinetic reaction of childhood” (“hyperactive”; “hyperactivity”;
“hyperkinesis”). Two publications used the term Attention Deficit
Disorder (ADD), introduced in the DSM-III in 1980. Studies in which
the diagnosis had been made after the introduction of the term ADHD in
the DSM-III-R used this term (see Fig. S1.3).
ADHD diagnostic criteria were often unreported; where they were,
in all but one study these were either DSM or ICD criteria (see Fig. 5,
Panel B). Twenty-four of the group studies used DSM criteria, ranging
from DSM-II to DSM-IV-TR, while six studies used ICD codes. Twelve
group studies reported ADHD subtypes. Eight case reports referred to
DSM criteria (DSM-III to DSM 5). Three case reports specified a subtype.
3.1.3.2.2. Comorbid disorders. Not all 39 group studies reported on
the presence or absence of comorbid disorders. Of the 25 that did, only
one excluded participants with comorbidities (Hammerness et al.,
2017). The remainder reported at least one comorbid disorder in
their sample, and 12 reported two or more comorbidities. Seven
group studies investigated cases of ADHD with specific comorbidities:
three with epilepsy (Fosi et al., 2013; Gucuyener et al., 2003; Mulas
et al., 2014); three with a tic disorder (Gadow et al., 1999; Nolan et al.,
1999; Riddle et al., 1995); and one by Kutlu et al. (2017), of cases with
oppositional defiant disorder (ODD) or comorbid conduct disorder
(CD). Thirteen of the case studies reported on comorbidities: one
reported that there were no comorbid disorders, eight reported one
comorbid disorder, and four reported more than one.
Either ODD or conduct disorder CD was most commonly reported as
the first or most prevalent comorbidity, followed by tic disorder or
Tourette Syndrome, and anxiety disorder. These disorders were also the
most commonly reported comorbid disorders overall (Table 5).
3.1.4. Predictors of outcome
3.1.4.1. MPH treatment. The type of MPH release formulation (e.g.
immediate or modified release) was often unreported, unclear, or
reported as mixed (see Fig. S1.4).
In 24 of the 67 studies, the type of MPH delivery was clearly spe-
cified, and in 50 studies, dosage was reported. The estimated most
common MPH treatment duration in studies ranged from 1 to 6 years3
(See Table 6).
3.1.4.2. Comparators. Comparators were highly varied (see Fig. 3).
Fifteen of the comparative studies had multiple comparators. Twelve
studies included comparisons or contrasts with other pharmacological
treatments including other stimulants (3 studies) and the non-stimulant
atomoxetine (6 studies). Many studies compared outcomes after long-
term MPH treatment with outcomes after either no, or less, exposure to
MPH treatment. Six of these used continuous measures of treatment
exposure (MPH and/or other treatment) e.g. duration or dosage as
predictors of outcome. The comparators for each comparative study are
given in Table 7.
3.1.5. Outcome categories
Our data-extraction tool had 15 headings for potential adverse
outcomes, including other notable neuropsychiatric outcome (Table 1). We
found no studies that investigated non-suicidal self-harm as an outcome
of long-term MPH treatment. Our heading “visual disturbances” was
designed to record studies in which visual disturbances of a neurolo-
gical origin were investigated. However, the only studies in which vi-
sual disturbances were reported were those in which the report sug-
gested that they were better categorised as psychotic-like symptoms.
Outcome categories for Comparative Studies are given in Table 7 and
for non-Comparative Studies in Table 8.
Table 1 (continued)
Heading Explanation Entry
Low Mood/Depression Was this potential neuropsychiatric outcome
investigated or reported in the study?
Yes/No
Anxiety Yes/No
Irritability/emotional reactivity Yes/No
Suicidal behaviour/ideation Yes/No
(Non-suicidal) Self harm Yes/No
Bipolar disorder Yes/No
Psychosis Yes/No
Psychotic like symptoms Yes/No
Substance use disorder Yes/No
Tics Yes/No
Other dyskinesias Yes/No
Seizures or EEG abnormalities Yes/No
Sleep disorders Yes/No
Visual disturbances Yes/No
Other notable neuropsychiatric outcome Potential neuropsychiatric outcome
investigated but not otherwise specified
Free text
Favours MPH (comparative studies) For comparative studies: did the outcome favour
MPH?
Yes, No, Proceed with Caution, Unclear, NA
Authors judgement of safety (non-comparative
studies)
For non-comparative studies: what was the
authors’ judgement of safety?
Yes, No, Proceed with Caution, Unclear, NA
Other comments Any other comments Free text
3 Five studies used Taiwan’s nationwide health insurance database. While a
mean duration of MPH treatment was not explicitly given as being over 12
months in these five studies, a study of treatment persistence using the same
database indicates that the proportion of cases of ADHD who persist with MPH
treatment for over 12 months is over 50% (Wang et al., 2016b).
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During data extraction, it became apparent that the research ques-
tions addressed by the group studies fell into two broad types. The first
type comprised questions regarding the safety or tolerability of long-
term (>12 months) MPH treatment by measuring adverse events/effects
(AEs) during long-term MPH treatment. Included in this group were
studies that investigated the risk of exacerbation of specific pre-existing
conditions or risk factors e.g. a history of tics or seizures. The second
type comprised questions regarding long-term outcomes for partici-
pants who had received or were still receiving long-term MPH treat-
ment. The primary aim of some of these studies were to investigate
potential medium-to-long-term benefits of long-term MPH treatment for
these outcomes, while for others it was to establish long-term risk. We
therefore added a post hoc variable to the evidence map in which we
categorised the group studies into these categories (see Fig. S1.5). Some
studies fell into a grey area between the two, being studies of medium-
term neuropsychiatric outcome immediately following a period of MPH
treatment. In these cases, two investigators conferred on categorisation,
and the decision was made on the basis of the nature of the primary
study question.
The AE studies were a mix of comparative and non-comparative
designs, including open-label extensions to clinical trials. In these
safety/tolerability studies, the adverse effects recorded or solicited were
often diverse, but studies only met our inclusion criteria if the effects
included at least one neuropsychiatric effect. In Outcome studies, the
evidence for potential adverse effects or outcomes was provided by
evaluation of neurological, psychiatric or behavioural symptoms. The
Fig. 1. Prisma flow chart for literature search.
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measures used to evaluate symptoms in these studies included both
broad and targeted symptom rating scales; ICD codes; and objective
markers (e.g. tic monitoring; EEG).
3.2. Summaries of findings by pharmacological comparators
Below we summarise the findings of studies that compared long-
term MPH treatment with other pharmacological treatments.
3.2.1. Atomoxetine
Of the six studies that included a comparison with atomoxetine, two
were investigations of adverse effects of treatment. In a large pharma-
covigilance study, Cortese et al. (2015) found significantly fewer neu-
ropsychiatric AEs overall for MPH than for Atomoxetine4. Haynes et al.
(2015) investigated factors predicting worsening ADHD severity, and
measured a range of AEs to MPH and atomoxetine treatment; and these
included sleep AEs5. We coded the result of this study as Unclear. The
other three studies used large national databases and each considered a
specific long-term outcome: Lee et al. (2016) investigated mood dis-
order6; Wang et al. (2016a), considered bipolar disorder7 and Liang
et al.(2018) considered suicidal behaviour.8 For all three outcomes, as
neither MPH nor atomoxetine treatment was associated with increased
risk, and long-term MPH treatment was associated with reduced risk,
we coded these results as Favours MPH.
We conclude that further large studies are needed to evaluate the
long-term risks and/or benefits of MPH vs atomoxetine with regard to
other long-term neuropsychiatric outcomes.
3.2.2. Other stimulants
Three studies compared MPH with other stimulants (e.g. dex-
amphetamine; pemoline; Adderall). Two investigated emergence of tics
(Lipkin et al., 1994; Varley et al., 2001), and compared MPH with
dexamphetamine and pemoline. While tic emergence rates were low in
both studies, neither study found any significant difference in tic
emergence rates between stimulants. We coded the results of Lipkin
et al. as Unclear. The children in the larger study by Varley et al. ex-
cluded children with a history of tics, and we coded the results of Varley
et al’s. larger study as Proceed with Caution for this population. Ghuman
et al. (2001) investigated AEs, including tics, in pre-schoolers (N=27)
treated with MPH, Adderall and dexamphetamine. As AE rate was
generally high for all three stimulants, with no significant difference
between stimulants, we coded the result for the comparative safety of
MPH as Unclear. We conclude that the evidence base for the relative
safety of MPH vs other stimulants with regard to tics is weak, as is the
evidence base for its relative safety in pre-schoolers.
3.2.3. Other pharmacological comparators
Two studies compared MPH with medications not primarily in-
dicated for ADHD. In an open-label RCT, Quinn and Rapoport (1975)
investigated anxiety in a sample of boys after a year’s treatment with
MPH, the antidepressant imipramine, or placebo and found no sig-
nificant differences in anxiety between any treatment.9 We coded this
result as Unclear. Using a large nationwide database, Steinhausen and
Bisgaard (2014) investigated SUD as an outcome following treatment
with either MPH, antipsychotic treatment, antidepressant treatment or
mixed treatment, and found a benefit for MPH but the opposite for
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antipsychotic and antidepressant treatments. We coded their results as
Favours MPH.
We conclude that for most neuropsychiatric outcomes, the evidence
base is weak regarding relative safety of long-term MPH over medica-
tions not primarily indicated for ADHD.
3.3. Summaries of findings by adverse outcome
The evidence regarding each potential adverse outcome is sum-
marised below. Codes for the results or authors’ conclusions for each
study are given in the final columns of Tables 2–4. Detailed narrative
summaries are given in S2, including details of the rating scales used.
3.3.1. Low mood or depression
Fourteen studies reported on low mood or depression as a potential
adverse outcome of long-term MPH treatment: eight comparative stu-
dies, three non-comparative studies, and three case reports. The evi-
dence regarding Low Mood/Depression is summarised in Table 9.
Several of the group studies provided evidence in favour of MPH
with regard to low mood/depression. These included three comparative
studies in children and young adults: two large cohort studies with
sample sizes> 1000 (Cortese et al., 2015; Lee et al., 2016) and an RCT
(Hechtman et al., 2004). It also included three non-comparative studies
(Edvinsson and Ekselius, 2018; Gadow et al., 1999; Kutlu et al., 2017).
However, the evidence from five smaller (N < 1000) comparative
studies was unclear (Ghuman et al., 2001; Hechtman et al., 1984;
Paternite et al., 1999; Philipsen et al., 2015; Schrantee et al., 2018).
One case study indicated the need for caution in the case of an MPH-
abusing youth (Garland, 1998). We conclude that the evidence base
regarding mood outcomes from long-term MPH treatment is relatively
strong, includes two well-powered comparative studies (Cortese et al.,
2015; Lee et al., 2016), and tends to favour MPH. A detailed narrative
summary is given in S2.2.
Fig. 2. Histograms of sample sizes for (left) comparative and (right) non-comparative group studies, broken out by study design. Numbers in white indicate number
of studies.
Table 5
Comorbidities. Specific comorbidities reported, with 1) the number of studies
reporting each comorbid disorder and 2) the number of studies reporting that
disorder as the only or most prevalent, comorbid disorder. Comorbid disorders
as listed in rank order of the number of studies reporting that disorder.
Comorbidity N studies reporting
as comorbidity
N studies reporting as
only, or most prevalent,
comorbidity
ODD/CD 15 11
Tics/Tourette syndrome 11 6
Anxiety 11 3
Substance use disorder 7 4
Depression 7 1
Intellectual disability
(IQ < 70)
7 1
Autism spectrum/
communication
6 0
Seizures/EEG abnormalities 5 4
Bipolar disorder 3 1
Psychosis/hallucinations 3 1
Specific learning impairment/
learning disability
3 1
Obsessive compulsive 2 1
Personality Disorders 2 1
Personality Disorders 1 1
Eating disorder 1 0
Sleep disorders 1 0
Feeding Disorder 1 0
Motor skills disorder 1 0
Mood Disorder 1 0
Table 6
Treatment durations. Estimated most common duration of MPH treatment in
included studies, rounded down to nearest whole number of years.
Most common duration of MPH
treatment
N total
studies
N group
studies
N case reports
1 year 32 23 9
2 years 13 7 6
3 years 8 5 3
4 years 3 1 2
5 years 6 1 5
6 years 5 2 3
Fig. 3. Comparators used in comparative studies. Numbers refer to number of
studies using that comparator. Numbers sum to more the number of com-
parative studies (N=28) as 15 studies used multiple comparators.
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3.3.2. Anxiety
Eleven studies reported on anxiety as a potential adverse outcome:
seven comparative studies, three non-comparative studies, and one case
report. The evidence regarding anxiety is summarised in Table 10.
Sample sizes for anxiety as an outcome were fairly small. Five group
studies (N< =118), including two comparative (Hechtman et al.,
1984; Kittel-Schneider et al., 2016) and three non-comparative
(Edvinsson and Ekselius, 2018; Gadow et al., 1999; Kutlu et al., 2017)
studies, provided evidence in favour of MPH, but the remaining five
(N< =103) comparative studies (Ghuman et al., 2001; Hechtman
et al., 2004; Quinn and Rapoport, 1975; Paternite et al., 1999;
Schrantee et al., 2018) were unclear. The single case study indicated
that MPH was safe/tolerated for this outcome (Guerdjikova and
McElroy, 2013). We conclude that the while the evidence with regard to
anxiety as an outcome of long-term MPH treatment tends to favour
MPH, the evidence base is relatively weak. A detailed narrative sum-
mary is given in S2.2.
3.3.3. Irritability/Emotional reactivity
Seven studies reported on irritability or emotional reactivity as a
potential adverse outcome: two comparative studies, four non-com-
parative and one case report. The evidence regarding irritability/emo-
tional reactivity is summarised in Table 11.
One large comparative study (Cortese et al., 2015) and all four
smaller non-comparative studies (Atzori et al., 2009; Edvinsson and
Ekselius, 2018; Kutlu et al., 2017; Wilens et al., 2005) provided evi-
dence in favour of MPH regarding irritability/emotional reactivity. A
small comparative study of pre-schoolers (Ghuman et al., 2001) and a
case report (Rosenfeld, 1979) were unclear. We conclude that the evi-
dence base regarding irritability/emotional reactivity outcomes of long-
term MPH treatment is limited, although it includes one well-powered
study (Cortese et al., 2015) that found in favour of MPH over ato-
moxetine. A detailed narrative summary is given in S2.3.
3.3.4. Suicidal behaviour/ideation
Nine studies reported on suicidal behaviour/ideation as a potential
adverse outcome: five comparative group studies and four case reports.
The evidence regarding suicidal behaviour/ideation is summarised in
Table 12. None of the included studies reported non-suicidal self-harm
as a potential adverse outcome.
All five comparative studies, including three large comparative co-
horts (Cortese et al., 2015; Huang et al., 2018; Liang et al., 2018) and
two smaller studies (Hechtman et al., 1984; Paternite et al., 1999)
provided evidence in favour of MPH regarding suicidal behaviour. Two
of the four case reports include cases where MPH had been used in
unsuccessful suicide attempts (Erkuran et al., 2016, Eryilmaz et al.,
2014), and two were of cases with suicidal ideation (Garland, 1998;
Rosenfeld, 1979). We conclude that the evidence base regarding sui-
cidal behaviour and long-term MPH treatment is relatively strong, and
tends to favour MPH. A detailed narrative summary is given in S2.4.
3.3.5. Bipolar disorder
Four studies reported on bipolar disorder as a potential adverse
outcome: Two large comparative studies, one non-comparative study,
and one case report. The evidence regarding bipolar disorder is sum-
marised in Table 13.
One large (N > 1000) comparative cohort provided evidence in
favour of MPH regarding bipolar disorder (Wang et al., 2016a). The
other (Jerrell et al., 2014) found slightly elevated risk, although in this
study, risk was also elevated by comorbid psychiatric diagnoses, sug-
gesting that treatment propensity may have been a confound. The only
two other studies for bipolar disorder as an outcome were a small non-
comparative retrospective chart review by Cherland and Fitzpatrick
(1999) that suggested a need for caution, and a case report of a complex
adult case (Guerdjikova and McElroy, 2013). We conclude that the
evidence base regarding bipolar disorder and long-term MPH treatmentTa
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is limited and unclear, although it includes two well-powered studies. A
detailed narrative summary is given in S2.5.
3.3.6. Psychosis and psychotic like symptoms
Fourteen studies reported on psychosis and/or psychotic-like
symptoms as a potential adverse outcome: four comparative studies,
one non-comparative study, and nine case reports. Studies that reported
visual disturbances have been included under this heading, as all were
of psychotic-like visual experiences, rather than neurological signs. The
evidence regarding Psychosis and Psychotic-like symptoms is sum-
marised in Table 14.
Three comparative studies provided evidence in favour of MPH: two
studies (Cortese et al., 2015; Paternite et al., 1999) provided evidence
that MPH reduces risk of psychotic-like symptoms, and one study
(Hechtman et al., 2004) that it reduces the risk hospitalisation for
psychosis. However, two comparative studies (Cherland and
Fitzpatrick, 1999; Shyu et al., 2015) indicate a need for caution. One of
these (Shyu et al., 2015) was a large cohort study that specifically
studied psychotic disorders as a potential adverse outcome of MPH
treatment. The authors found an elevated risk associated with MPH,
although they also found that ADHD itself was a significant risk factor
for psychosis. In addition, the authors of four case reports (Gross-Tsur
et al., 2004; Lee, 2016; Rashid and Mitelman, 2007; Young, 1981)
concluded that psychosis may have resulted from MPH treatment. We
conclude that these findings indicate that more research is needed into
the relationship between ADHD and psychosis, and into whether MPH
moderates that risk, as well as research into individual risk-factors for
MPH-related psychosis in young people with ADHD. A detailed narra-
tive summary is given in S2.6.
3.3.7. Substance use disorders
Sixteen studies reported on SUD as a potential adverse outcome:
seven comparative studies, one non-comparative study, and eight case
reports including 2 cases from one case series. The evidence regarding
SUD is summarised in Table 15.
Six of the comparative studies (Ginsberg et al., 2015, Hammerness
et al., 2017; Hechtman et al., 1984; Mannuzza et al., 2008; Paternite
et al., 1999; Steinhausen and Bisgaard, 2014), including one large
comparative cohort (Steinhausen and Bisgaard, 2014), provide evi-
dence in favour of MPH regarding SUD, as do five case reports of adults
with comorbid SUD (Guerdjikova and McElroy, 2013; Imbert et al.,
2013; Khantzian et al., 1984; both cases reported by Schubiner et al.,
1995). In addition, one non-comparative study suggests that long-term
MPH treatment in adults without prior SUD does not present a risk for
new SUD (Torgersen et al., 2012). However, three case reports of abuse
of prescribed MPH suggest that caution is warranted in this regard
(Garland, 1998; Goyer et al., 1979; Jaffe, 1991). We conclude that the
evidence base for SUD outcomes and long-term MPH treatment is re-
latively strong, includes one well-powered study that compared MPH
with antipsychotic and antidepressant treatment, and tends to favour
MPH. A detailed narrative summary is given in S2.7.
3.3.8. Tics and other dyskinesias
Fourteen studies reported on tics and/or other dyskinesias as a
potential adverse outcome of MPH treatment: five comparative studies,
four non-comparative studies and five case reports. The evidence re-
garding tics and other dyskinesias is summarised in Table 16.
Several of the group studies were of children with a history of tics or
tic disorder. These included two withdrawal-challenge studies (Riddle
et al., 1995; Nolan et al., 1999) a comparative cohort (Varley et al.,
2001), and a noncomparative study (Gadow et al., 1999). Three of these
indicated a need for caution (Gadow et al., 1999; Riddle et al., 1995;
Varley et al., 2001), while one (Nolan et al., 1999) was unclear.
Of the group studies in which participants with tics or tic disorder
were either excluded or not specifically recruited, three non-compara-
tive studies (Atzori et al., 2009; Edvinsson and Ekselius, 2018; WilensTa
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et al., 2005) concluded that MPH was safe/well-tolerated with regard to
tics, while two comparative studies (Ghuman et al., 2001; Lipkin et al.,
1994), including one of pre-schoolers (Ghuman et al., 2001) were un-
clear.
The five case reports (Kazanci et al., 2015; Lee, 2016; Sprafkin and
Gadow, 1993; Waserman et al., 1983; Weiner et al., 1978) include three
cases with pre-existing tics (Sprafkin and Gadow, 1993; Waserman
et al., 1983). We conclude that more research is needed regarding the
safety and management of long-term MPH in those with comorbid tics
or tic disorder. A detailed narrative summary is given in S2.8.
3.3.9. Seizures or EEG abnormalities
Nine studies reported on seizures or EEG abnormalities as a po-
tential adverse outcome of MPH treatment: two comparative studies,
four non-comparative group studies, and three case reports. The evi-
dence regarding seizures or EEG abnormalities is summarised in
Table 17.
Evidence for the safety of MPH treatment in children with ADHD
and a history of seizures or abnormal EEG is provided by four group
studies (Fosi et al., 2013; Gucuyener et al., 2003; Hemmer et al., 2001;
Mulas et al., 2014) as well as two cases studies of children with a his-
tory of seizures (Ickowicz, 2002; Socanski et al., 2018). The authors of
two of the group studies (Hemmer et al., 2001; Mulas et al., 2014)
suggest proceeding with caution nonetheless. Evidence regarding
emergence of seizures or EEG abnormalities in children with no prior
history of seizures was provided by two group studies (Cortese et al.,
2015; Weiss et al., 1975) and a case study (Schertz and Steinberg,
2008). We conclude that while the evidence is limited and unclear, the
studies do not indicate evidence for seizures as an AE of MPH treatment
in children with no prior history. We conclude that more research is
needed into the safety of long-term MPH in children and young people
at risk of seizures. A detailed narrative summary is given in S2.9.
3.3.10. Sleep disorders
Eleven studies reported on sleep disorders as a potential adverse
outcome of long-term MPH treatment: five comparative studies, three
non-comparative studies and three case reports. The evidence regarding
sleep disorders is summarised in Table 18.
One large comparative study (Cortese et al., 2015) indicates that
atomoxetine may cause fewer sleep AEs than MPH. The results of the
other four comparative studies (Corkum et al., 1999; Gau and Chiang,
2009; Ghuman et al., 2001; Haynes et al., 2015), using a range of
comparators, are unclear. However, all three non-comparative studies
of AEs indicate that MPH is safe/well-tolerated in this regard (Atzori
et al., 2009; Edvinsson and Ekselius, 2018; Wilens et al., 2005), as does
one of the two case studies (Guerdjikova and McElroy, 2013). Two
studies concluded that the relationship between sleep disorders and
ADHD is complex (Corkum et al., 1999; Gau and Chiang, 2009). We
conclude that more research is needed into the relationship between
ADHD, sleep, and long-term MPH treatment. A detailed narrative
summary is given in S2.10.
Table 11
Irritability/Emotional reactivity. Studies reporting Irritability/Emotional reactivity as a potential adverse outcome.
IRRITABILITY/EMOTIONAL REACTIVITY
Study N Design Comparison Sample description Measures
Comparative Studies:
Favours MPH Cortese et al., 2015 2331 Cohort Atomoxetine Children and youth with ADHD, mostly male AEs*
Unclear Ghuman et al., 2001 27 Cohort Dexamphetamine, Adderall Pre-schoolers with ADHD, mostly male SERF (AEs)
Non comparative studies:
MPH safe Wilens et al., 2005 228 Prospective open label
longitudinal study
– Children and youth with ADHD, mostly male: tics,
seizures, psychosis excluded
AEs
Atzori et al., 2009 134 Prospective open label
longitudinal study
– Children with ADHD, mostly male AEs
Kutlu et al., 2017 118 Prospective open label
longitudinal study
– Boys with ADHD+CD/ODD CBCL
Edvinsson and
Ekselius, 2018
112 Retrospective cohort – Adults with ADHD AEs
Case report:
Unclear Rosenfeld, 1979 1 Case Report – Boy with ADHD
Table 12
Suicidal behaviour/ideation. Studies reporting Suicidal behaviour/ideation as a potential adverse outcome.
SUICIDAL BEHAVIOUR/IDEATION
Study N Design Comparison Sample description Measure
Comparative Studies:
Favours MPH Hechtman et al.,
1984
76 Cohort MPH v untreated ADHD, controls Adults with ADHD SADS, SCL-90
Paternite et al., 1999 97 Cohort Different dosages; treatment duration Young adult men with ADHD SADS-L, MMPI
Cortese et al., 2015 2331 Cohort MPH v atomoxetine Children and youth with ADHD,
mostly male
AEs
Liang et al., 2018 84,898 Cohort Different durations of treatment, no
treatment, atomoxetine
Youth under 18 with ADHD ICD-9 codes: E950–E959
Huang et al., 2018 20,574 Cohort No treatment; treatment < 1 year;
atomoxetine
Adolescents and young adults with
ADHD
ICD9-codes for suicide
attempts
Case Reports
Caution Garland, 1998 1 Case Report – Boy with ADHD and intranasal MPH
abuse
Erkuran et al., 2016 1 Case Report – Boy with ADHD
Unclear Rosenfeld, 1979 1 Case Report – Boy with ADHD
Eryilmaz et al., 2014 1 Case Report – Boy with ADHD
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3.3.11. Other notable neuropsychiatric outcomes
Three studies reported on “aggression” or “hostility” as an adverse
effect, and one reported on “personality changes”. The evidence re-
garding these outcomes is summarised in Table 19.
Two non-comparative studies (Kutlu et al., 2017; Wilens et al.,
2005) provide evidence that MPH is safe/well-tolerated with regard to
aggression or hostility as an AE, while the evidence from one com-
parative study of pre-schoolers (Ghuman et al., 2001) is unclear. Only
one study reported on personality changes (Haynes et al., 2015), with
no clear conclusion. We conclude that there is limited evidence re-
garding long-term MPH treatment and other neuropsychiatric outcomes
and that further research may be needed into the relationship between
long-term MPH treatment and aggression/hostility. A detailed narrative
summary is given in S2.11. No other notable neuropsychiatric effects
were reported specifically as potential adverse outcomes of treatment.
3.4. Overall result summary
Of the comparative studies, only one (Cortese et al., 2015) reported
an outcome (sleep disorders) that we coded as Favours Comparator
(atomoxetine). Of the seven comparative studies with a sample size>
1000, we coded six, including Cortese et al.’s, 2015 study, as Favours
MPH overall, and one, the study by Shyu et al. (2015) of schizophrenia
spectrum and other psychotic disorders, as Proceed with Caution. Of the
smaller studies (N < 1000) we coded eight as Favours MPH overall,
three as Proceed with Caution, and nine as Unclear.
The non-comparative group studies were all relatively small studies
(N < 1000), and we coded six as Safe/well-tolerated, two as Proceed
with Caution and one as Unclear. Of the case-studies, we coded seven as
Safe/well-tolerated, eleven as Proceed with Caution, four as Not Safe/well-
tolerated and four as Unclear.
These codings, with sample sizes where relevant, are shown gra-
phically in Fig. 4.
4. Discussion
This evidence map of studies addressing the potential adverse
neuropsychiatric effects of long-term MPH treatment for ADHD reveals
a great deal of between-study methodological variability. Comparative
studies spanned a wide range of comparators: placebo/no treatment;
other pharmacological and non-pharmacological treatments; and dif-
ferent MPH treatment regimens, treatment durations or age of onset of
treatment. The heterogeneity also extends to the range of populations
studied, from pre-schoolers to adults, as well as to specific at-risk
Table 13
Bipolar Disorder. Studies reporting Bipolar Disorder as a potential adverse outcome.
BIPOLAR DISORDER
Study N Design Comparison Sample description Measure
Comparative Studies:
Favours MPH Wang et al., 2016a, 289,840 Cohort Atomoxetine, no treatment Children with ADHD, mostly
male
ICD-9-CM codes for
BD
Caution Jerrell et al., 2014 22,797 Cohort Atomoxetine, duration of
treatment
Children and adolescents with
ADHD
ICD-9-CM codes for
BD
Non comparative studies:
Caution Cherland and Fitzpatrick,
1999
98 Retrospective chart
review
– Children with ADHD, mostly
male
AEs
Case Reports:
MPH safe Guerdjikova and McElroy,
2013
1 Case Report – Woman with bulimia, ADHD,
bipolar
Table 14
Psychosis/Psychotic-like Symptoms. Studies reporting psychosis or psychotic-like symptoms as a potential adverse outcome.
PSYCHOSIS/PSYCHOTIC-LIKE SYMPTOMS
Study N Design Comparator Sample description Measure
Comparative Studies:
Favours MPH Paternite et al., 1999 97 Cohort Different dosages and duration Young adult men with ADHD SADS-L, MMPI
Hechtman et al., 2004 103 RCT MPH+BT and MPH+attentional
control
Children and youth with ADHD CDI
Cortese et al., 2015 2331 Cohort Atomoxetine Children and youth with ADHD,
mostly male
AEs
Caution Shyu et al., 2015 146,098 Cohort No treatment Children and youth with ADHD,
mostly male
ICD-9-CM codes
Non-comparative studies:
Caution Cherland and Fitzpatrick,
1999
98 Retrospective chart
review
– Children with ADHD, mostly
male
AEs
Case studies:
Caution Lucas and Weiss, 1971 1 Case Report – 15 year old hyperkinetic girl
Weiner et al., 1978 1 Case Report – Boy with hyperactive
behaviour
Chammas et al., 2014 1 Case Report – Boy with ADHD
Ekinci et al., 2017 1 Case Report – Boy with ADHD
MPH not safe Young, 1981 1 Case Report – Boy with hyperactive
behaviour
Gross-Tsur et al., 2004 1 Case Report – Boy with ADHD (Case 1 of 3)
Rashid and Mitelman,
2007
1 Case Report – Boy with ADHD
Lee, 2016 1 Case Report – Woman with ADHD
Unclear Rosenfeld, 1979 1 Case Report – Boy with ADHD
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groups, such as pre-schoolers, children with comorbid neurological
disorders, and offenders.
The study questions themselves were also heterogeneous: some
studies set out specifically to monitor adverse outcomes, either open-
endedly as in pharmacovigilance designs, or targeted at specific adverse
outcomes, (e.g. tics, psychosis, or EEG abnormalities). In others, the
study question is framed as investigating a potential long-term benefit,
(e.g. potential reduced risk of adverse adult psychiatric outcomes).
Studies also varied as to whether the primary purpose of the study
was to determine the effects of long-term treatment or long-term effects
of treatment. In this review, we only included studies in which the most
common treatment duration was over one year; however, there may be
important long-term effects, both adverse and beneficial, of shorter
MPH treatment durations. Future investigators may want to make the
potentially important distinction between adverse neuropsychiatric ef-
fects of prolonged treatment during the treatment period (e.g. tic
emergence; sleep disturbance), and long-term neuropsychiatric out-
comes of MPH treatment that lie outside the core deficits of ADHD (e.g.
risk elevation or reduction of neuropsychiatric disorders in adulthood).
These could include long-term effects of relatively short treatment
durations, as well as effects that persist after cessation of treatment.
The evidence map highlights the potential confound between neu-
ropsychiatric and behavioural outcomes of long-term treatment and
neuropsychiatric symptoms that may increase the probability of long-
term treatment (neuropsychiatric and behavioural treatment propensity
factors). Many of the studies included were of patients with comorbid
symptoms that were also listed as our potential adverse outcomes of
interest; moreover, these comorbid symptoms may themselves some-
times be adverse outcomes resulting from the stresses of living with
ADHD. This confound underscores the importance of self-controlled
case-series approaches using large databases e.g. Man et al. (2017,
2016), and for large long-term prospective studies.
However, the evidence map also highlights the importance of single
case-level studies, study discontinuation data, and details from retro-
spective chart reviews. While large studies can provide confidence that
a treatment is generally beneficial, and/or AEs generally mild and in-
frequent, these individual-level studies underscore the need for re-
commendations for caution in specific cases, even for neuropsychiatric
outcomes for which evidence indicates overall lowering of long-term
risk by long-term MPH treatment. Further research is needed into the
predictors of serious, if rare, adverse outcomes, for example in the
presence of particular comorbid disorders, such as seizures, psychotic
symptoms or tics. Again, studies using large databases, particularly
those using self-controlled case series methodology may shed light on
these risks.
4.1. Clinical summary
Despite the heterogeneity of the studies, a provisional clinical
summary can be made. For depressive symptoms, overall, the studies
suggest that long-term MPH treatment has favourable outcomes, in-
cluding reduced suicide in ADHD. As depression is one of the com-
monest mental health conditions and suicide is a major public health
concern, this is important. Moreover, most of the studies suggest that
long-term MPH is safe with regards to anxiety and irritability, at least in
those above preschool age. The evidence from studies looking at sub-
stance abuse risk generally indicates that long-term MPH use is safe and
predicts good long-term outcomes, although caution is indicated with
regard to the abuse of prescribed MPH in high risk adolescents.
Several of the studies looking at either psychosis or tics suggest that
long-term MPH use is generally safe, although case reports do indicate
that MPH should be used with caution in those prone to psychosis or
tics. Some evidence suggests that both psychosis and tics remitted after
withdrawal of methylphenidate indicating these AEs may be short term.
More studies are needed in bipolar disorder and seizures as the evi-
dence is currently sparse and unclear on these outcomes. SleepTa
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disorders, MPH and ADHD appear to have a complex interaction and
most studies available are unclear regarding long term outcomes.
Studies exploring dosing and timing of MPH are warranted in this area.
Overall, these findings do not suggest that long-term MPH is unsafe
with regard to neuropsychiatric outcomes, and several studies suggest
that long-term MPH may reduce depression and suicide in ADHD.
Although the evidence suggests an elevated risk of psychosis and tics,
case reports describe remission on discontinuation. Caution is advised
in specialist groups such as pre-school children, those with tics, and
adolescents at risk for substance misuse. Given the evidence for positive
neuropsychiatric outcomes versus the evidence for risks, long-term
MPH use in ADHD would appear to be justified. However, the evidence
also highlights the need for careful and regular monitoring of long-term
MPH in ADHD by a specialist.
4.2. Limitations
A limitation of this review is that as we only included studies in
which it was possible to isolate long-term MPH treatment from long-
term pharmacological treatment more generally, some important stu-
dies of long-term medication, were omitted. Notable exclusions re-
sulting from this inclusion criterion are the case-controlled 10-year
longitudinal study by Biederman et al. (2009) on the effects of stimu-
lant medication on adult psychiatric outcomes, and studies by Chang
et al. on SUD (2014) and depression (2016), as well as the findings from
the MTA study (Molina et al., 2009; MTA Cooperative Group, 2004).
However, these omissions serve to underscore the importance of both
investigations into the potential neuropsychiatric harms of long-term
exposure to specific pharmacological treatments for ADHD, and in-
vestigations into the potential long-term neuropsychiatric harms of
unsuccessfully treated ADHD.
We also note as a limitation that the second wave of the search
(articles published after January 2013) only included articles written in
English. While only one non-English study from the first wave met our
inclusion criteria, it remains possible that later non-English publications
may meet these criteria.
Table 17
Seizures or EEG abnormalities. Studies reporting seizures or EEG abnormalities as a potential adverse outcome.
SEIZURES OR EEG ABNORMALITIES
Study N Design Comparison Sample description Measures
Comparative Studies:
Caution Hemmer et al., 2001 205 Cohort No treatment or
placebo
Children with ADHD assessed for EEG abnormalities prior to
starting stimulant medication, mostly male
EEG, seizures
Unclear Cortese et al., 2015 2331 Cohort MPH v atomoxetine Children with ADHD AEs
Non-comparative studies:
MPH safe Gucuyener et al.,
2003
119 Prospective open-label
trial
– Children and youth with ADHD+epilepsy or EEG
abnormalities, mostly male
EEG
Fosi et al., 2013 18 Retrospective chart
review
– Children and youth with ADHD+epilepsy, mostly male Seizure Frequency
Caution Mulas et al., 2014 17 Retrospective chart
review
– Children and youth with ADHD+epilepsy EEG and seizure
history
Unclear Weiss et al., 1975 22 retrospective cohort
design
– Hyperactive children EEG
Case reports:
Safe Ickowicz, 2002 1 Case Report – Boy with ADHD
Socanski et al., 2018 1 Case Report – Boy with ADHD
Caution Schertz and Steinberg,
2008
1 Case Report – Girl with ADHD
Table 18
Sleep disorders. Studies reporting sleep disorders as a potential adverse outcome.
SLEEP DISORDERS
Study N Design Comparator Sample description Measures
Comparative studies:
Favours comparator Cortese et al., 2015 2331 Cohort Atomoxetine Children with ADHD AEs
Unclear Corkum et al., 1999 172 Cohort No active treatment Children SLQ
Ghuman et al., 2001 27 Cohort Dexamphetamine, Adderall Pre-schoolers with ADHD, mostly
male
SERF (AEs)
Gau and Chiang, 2009 281 Cohort No current MPH treatment; healthy
controls
Children with ADHD Sleep Disturbance
Questionnaire
Haynes et al., 2015 704 Cohort Atomoxetine Children and youth with ADHD,
mostly male
AEs
Non-comparative studies:
MPH safe Wilens et al., 2005 228 Prospective open-label trial – Follow-up from Wilens et al., 2005 AEs
Atzori et al., 2009 134 Prospective open label study – Children with ADHD, mostly male AEs
Edvinsson and Ekselius,
2018
112 retrospective cohort design – Adults with ADHD AEs
Case reports:
MPH safe Guerdjikova and
McElroy, 2013
1 Case Report – Woman with ADHD+bulimia,
bipolar
Caution Garland, 1998 1 Case Report – Boy with ADHD and intranasal
MPH abuse
Unclear Villafuerte-Trisolini
et al., 2017
1 Case Report – 10 year old boy with catathrenia
(sleep disorder)
Somnogram
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4.3. Conclusion
We conclude that the evidence base regarding both adverse and
beneficial neuropsychiatric effects of long-term MPH treatment would
be improved by more studies that make use of large longitudinal da-
tabases, focus on specific neuropsychiatric outcomes, and compare
outcomes from long-term MPH treatment not only with outcomes from
other treatments but also with outcomes following no pharmacological
intervention.
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Other notable neuropsychiatric outcomes. Studies reporting any other notable potential neuropsychiatric adverse outcome.
OTHER NOTABLE NEUROPSYCHIATRIC OUTCOMES
Study N Design Comparator Sample description Outcome Measure
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Agitation/
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